IMMUNOTHERAPY AND SURVIVAL RATE OF PATIENTS WITH CERVICAL AND OVARIAN CANCER

=jmiiZ[hevguo\aZ\bkbfhklbhle_q_gbyQbkeh[hevguo % JZdr_cdbfZldb, IIB kl.KEL, n=21 14 66,7±10,3KEL + KBL, n=18 16 88,9±7,4 KEL + KBL + :BL, n=20 19 95,0±4,9 JZdr_cdbfZldb, III kl.KEL, n=21 13 61,9±10,6KEL + KBL, n=18 14 77,8±9,8 KEL + KBL + :BL, n=17 15 88,2±7,8 JZdybqgbdh\, III kl.IOL, n=19 12 63,2±11,1IOL + KBL, n=16 13 81,3±9,8 IOL + KBL + :BL, n=18 16 88,9±7,4 JZdybqgbdh\, IV kl.IOL, n=18 7 38,9±11,5IOL + KBL, n=17 12 70,6±11,1IOL + KBL + :BL, n=17 13 76,5±10,3